vimarsana.com

Page 12 - Pfizer Global Product Development News Today : Breaking News, Live Updates & Top Stories | Vimarsana

FDA to Review Ritlecitinib for Alopecia Areata

The FDA has accepted for filing the NDA for ritlecitinib for patients 12 years of age and older with alopecia areata.

Michael corboEuropean academy of dermatologyDrug administrationPfizer global product developmentNew drug applicationAlopecia toolChief development officerPfizer global product

Pfizer Ends Development of LMNA-Related Dilated Cardiomyopathy Drug

Pfizer has discontinued the clinical development of PF-07265803 for the treatment of patients with LMNA-related dilated cardiomyopathy.

Chris boshoffPfizer global product developmentChief development officerRare diseasePfizer global product

Pfizer Cancels Phase III Drug Trial for Cardiovascular Disease

Lackluster initial results forces Pfizer to discontinue Phase III trial on a potential drug for symptomatic dilated cardiomyopathy (DCM).

United statesMikael dolstenDavidl ryanChris boshoffRare disease at pfizer global product developmentPfizer worldwide researchBoston globeArray biopharmaRare diseasePfizer global product developmentWorldwide researchFizer cancels phase iii drug trial for cardiovascular disease

Pfizer, MorphoSys and Incyte Enter into Clinical Trial Collaboration for Monjuvi® (tafasitamab-cxix) in Combination with TTI-622, a Fusion Protein Directed Against CD47

DGAP-News: MorphoSys AG / Key word: Agreement/Miscellaneous Pfizer, MorphoSys and Incyte Enter into Clinical Trial Collaboration for Monjuvi® in Combination with TTI-622, a Fusion. | June 13, 2022

New yorkUnited statesUnited kingdomLance leopoldCatalina lovemanChris boshoffChristine chiouJenifer antonacciDevelopment officerXencor incAmerican society of hematologyPfizer incPublic affairsGroup viceDrug administrationPfizer global product development

Pfizer, MorphoSys and Incyte Enter into Clinical Trial Collaboration for Monjuvi® (tafasitamab-cxix)

DGAP-News: MorphoSys AG / Key word(s): Agreement/MiscellaneousPfizer, MorphoSys and Incyte Enter into Clinical Trial Collaboration for Monjuvi® (tafasitamab-cxix) in Combination with TTI-622, a Fusion Protein Directed Against CD47 13.06.2022 / 22:01 The issuer is solely responsible for the content of this announceme.

New yorkUnited statesUnited kingdomLance leopoldCatalina lovemanChris boshoffChristine chiouJenifer antonacciDevelopment officerXencor incDistribution servicesAmerican society of hematologyPfizer incPublic affairsGroup viceDrug administration

vimarsana © 2020. All Rights Reserved.